PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Both companies show declining cash positions (-8.57% vs AGEN's -52.22%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Below half of AGEN's -52.22%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Other current assets growth < half of AGEN's 53.89%. David Dodd sees a leaner approach to short-term items.
-8.67%
Below half of AGEN's -49.85%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.20%
≥ 1.5x AGEN's -0.65%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Less than half of AGEN's -24.23%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-7.12%
≥ 1.5x AGEN's -2.12%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Below half of AGEN's -18.44%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-100.00%
Above 1.5x AGEN's -9.72%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Similar yoy changes to AGEN's -100.00%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Exceeding 1.5x AGEN's 39.94%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-20.28%
Above 1.5x AGEN's -0.01%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
Less than half of AGEN's -1.21%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Above 1.5x AGEN's -0.58%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
Similar yoy to AGEN's -3.21%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
Below half AGEN's 63.81%. Michael Burry sees potential underperformance in building shareholder capital.
-8.62%
Below half AGEN's -18.44%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Similar yoy to AGEN's -100.00%. Walter Schloss notes parallel moves in the investment portfolio.
-7.46%
Less than half of AGEN's -31.79%. David Dodd sees less overall debt expansion vs. competitor.
8.60%
Less than half of AGEN's 180.78%. David Dodd sees better deleveraging or stronger cash buildup than competitor.